Furthermore, Bieke Broux et al. found that fractalkine is upregulated in the cerebrospinal fluid of MS patients already after the first clinical manifestation and in the brain lesions of chronic MS patients. This evidence concerns the gene CX3CL1 and myeloid sarcoma.